title: The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
abstract: Pharmacological treatments currently available to treat obsessive-compulsive disorder (OCD) rarely produce remission. This Editorial aims to encourage more targeted research based on the specific OCD symptoms patients primarily present with. Specific OCD symptoms have been associated with distinct clinical characteristics, aetiological hypotheses and treatment responses. Treatment studies should use these findings to develop more targeted pharmacotherapy for patients with OCD.
authors.affiliation: The University of Sydney, Nepean Hospital, Sydney Medical School, Discipline of Psychiatry , PO Box 63, Sydney/Penrith, New South Wales 2751 , Australia +61 2 4734 2585 ; +61 2 4734 3343 ; vbrakoulias@bigpond.com , vlasios.brakoulias@sydney.edu.au.
authors.forename: Vlasios
authors.initials: V
authors.lastname: Brakoulias
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D017367:Selective Serotonin Reuptake Inhibitors
keywords: obsessive–compulsive disorder; pharmacotherapy; subtypes